OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Yuan on the DEMETHER Trial of Induction T-DXd Plus HP Maintenance in HER2+ Breast Cancer

October 30th 2025

Yuan Yuan, MD, PhD, discusses a new treatment approach involving induction T-DXd followed by trastuzumab/pertuzumab maintenance in HER2-positive disease.

Dr Hurvitz on the Rationale for Targeting PI3K and mTOR in PIK3CA Wild-Type HR+/HER2-Negative Breast Cancer

October 30th 2025

Sara A. Hurvitz, MD, FACP, explains the clinical rationale for targeting the PI3K/mTOR pathways with gedatolisib in the VIKTORIA-1 trial.

Dr Jänne on Key Areas of Ongoing Debate in EGFR+ NSCLC

October 30th 2025

Pasi A. Jänne, MD, PhD, discusses key areas of debate in lung cancer management, with a focus on defining the optimal duration of adjuvant targeted therapy.

Dr Le on Innovations and Future Directions for KRAS Inhibition in NSCLC

October 30th 2025

Xiuning Le, MD, PhD, discusses the current landscape of KRAS G12C inhibitors and emerging strategies for optimizing KRAS inhibition in NSCLC.

Dr Xie on the ARTEMIS-002 Study Investigating HS-20093 in Relapsed/Refractory Sarcomas

October 30th 2025

Lu Xie, MD, discusses the design of the phase 2 ARTEMIS-002 trial.

Dr Wang on the Efficacy of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

October 30th 2025

Pule Wang, MD, discusses findings from a retrospective study of CNS bridging radiation therapy prior to CAR T-cell therapy in B-cell lymphomas.

Dr Tarantino on Clinical Implications of the neoCARHP Trial in HER2+ Breast Cancer

October 30th 2025

Paolo Tarantino, MD, PhD, discusses the clinical utility of data from the phase 3 neoCARHP trial in patients with HER2-positive early breast cancer.

Dr Visco on the Role of RBAC Dose Reductions for High-Risk MCL

October 30th 2025

Carlo Visco, MD, highlights the clinical relevance of reducing the dose of certain RBAC components when administering this regimen in high-risk MCL.

Dr Randall on Incorporating Ultrasound STS Surveillance Into Clinical Practice

October 30th 2025

R. Lor Randall, MD, FACS, discusses a new STS surveillance algorithm based on findings that show the comparable diagnostic utility of ultrasound and MRI.

Dr Mehta on the Mitigation of Common Immunotherapy-Related Toxicities in Urothelial Cancer

October 30th 2025

Amit Mehta, MD, outlines the common toxicities encountered with immunotherapy-containing regimens in urothelial cancer and strategies to mitigate them.

Dr Saad on the Importance of Timing When Incorporating Radium-223 Into Prostate Cancer Treatment

October 29th 2025

Fred Saad, MD, discusses the importance of timing when incorporating radium-223 into prostate cancer treatment.

Dr Dreyling on the Evolving Role of BTK Inhibitors in MCL Management

October 29th 2025

Martin Dreyling, MD, speculated on the future role of BTK inhibitors either alone or in non-cytotoxic chemotherapy combinations for patients with MCL.

Dr Tagawa on the PSMAddition Trial of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

October 29th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the design the PSMAddition trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Gupta on Future Directions With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

October 29th 2025

Shilpa Gupta, MD, discusses future research directions for enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Dr Lynam on the Clinical Implications of Targeted Therapies in Ovarian Cancer

October 29th 2025

Sarah Lynam, MD, discusses the clinical applicability of mirvetuximab soravtansine and trastuzumab deruxtecan in recurrent ovarian cancer.

Dr Mouhieddine on Future Directions With Ferritin and ALC as Biomarkers in Myeloma

October 28th 2025

Tarek Mouhieddine, MD, discusses future research directions with ferritin and ALC as biomarkers of response to bispecific antibodies in myeloma.

Dr Lee on the Role of SABR in Non–Small Cell Lung Cancer Management

October 28th 2025

Percy Lee, MD, discussed the use of SABR within the larger radiation therapy paradigm for the management of non–small cell lung cancer.

Dr Jain on Persisting Gaps in Defining Disease Modification in Polycythemia Vera and Myelofibrosis

October 27th 2025

Akriti G. Jain, MD, detailed the current unmet needs in polycythemia vera and myelofibrosis, including how to define disease modification.

Dr Sweis on the Potential for XmAb819 to Fill Treatment Gaps in Refractory RCC

October 24th 2025

Randy F. Sweis, MD, discusses shares how XmAb819 may address the need for effective therapies after progression on standard regimens in RCC.

Dr Peters on Obrixtamig Plus Atezolizumab/Chemo in First-Line ES-SCLC

October 24th 2025

Solange Peters, MD, PhD, discusses findings for obrixtamig plus atezolizumab/chemotherapy in first-line extensive-stage small cell lung cancer.